Clinigen Raises $80 Mil. In Rare U.K. Flotation While Europe's Wellington Partners Raises $91 Mil. For New Life Sciences Fund
This article was originally published in The Pink Sheet Daily
Hopes in Europe’s cash-strapped biotech sector were rekindled when specialty drug and contract services company Clinigen said it will be Britain’s first public pharma listing in five years and by investors from Europe, the U.S. and the Middle East piling into a new life sciences investment fund set up by pan-European VC firm Wellington Partners.
You may also be interested in...
Financings Of The Fortnight: Secondary Offerings Up From Pace Set In 2010 And 2011
Plus news on recent financings by Genkyotex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.
e-Therapeutics Explores Network Pharmacology For Drug Discovery, Moves First Of Its Drugs Into Clinical Studies
The U.K. company e-Therapeutics outlines its novel "network pharmacology" approach for discovery R&D, its product pipeline, and collaboration plans as it moves its first product, with potential in cancer, into Phase I studies.
New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding
The U.K.'s Cancer Research Technology and the European Investment Fund join forces to launch an asset-centric investment fund to bridge the development gap, the third new U.K. fund in two weeks.